CorrDyn

Is a machine coming for your job in biotech? Not from the view of Michael Nally, CEO at Generate:Biomedicines. He sees AI and ML as tools that augment scientists, but believes that the people within companies are and will remain critical to success. For more on how AI-driven drug development is changing the biotech and pharmaceutical industries, listen to Episode 23 of Data in Biotech. Apple: https://lnkd.in/e8y_hNUJ Spotify: https://lnkd.in/ekh-FwKM  

How do you decide, through the modeling process, which proteins you're going to take into the lab and gather data on?   Ryan Mork, Director of Data Science at Evozyne, gives an overview of the approaches his team takes to making this decision. He speaks to the value of selecting a range of proteins based on different criteria to get a full idea of what is possible.   This episode of Data in Biotech goes into detail on the process of designing proteins using AI and how to evaluate both models and the biomolecules generated. Catch the full interview with Ryan here:   Spotify: https://lnkd.in/e4BA_Zwb Apple: https://lnkd.in/eRYvmsUT

“Imagine you’re trying to design a hand to hold a pencil.”   Ryan Mork, Director of Data Science at Evozyne, uses this analogy to break down the concept of enzyme structure and movement, as it needs to be understood by a data science team looking to develop biomolecules.   In this episode of Data in Biotech, Ryan, alongside host Ross Katz, takes a deep dive into using Gen AI to design new therapeutic proteins. To hear the conversation in full, listen here: Spotify: https://lnkd.in/e4BA_Zwb Apple: https://lnkd.in/eRYvmsUT

We've got a new episode of Data in Biotech! This week we're joined by Parul Bordia Doshi from Cellarity. This was a fascinating conversation with Ross Katz that took us from exploring some of the biggest challenges facing Chief Data Officers, particularly for organizations with data-centric propositions, to looking at some of the practical approaches that ensure data scientists can extract the maximum amount of value from all available data. We also covered: • The benefits that come through hiring multilingual, multidisciplinary teams and putting a strong focus on collaboration. • How Cellarity is using GenAI and single-cell multiomics to design therapies that target the entire cellular system. • The future of data science for drug discovery, plus a look at Cellarity’s ongoing collaboration with Novo Nordisk on the development of novel therapeutics. Listen wherever you get your podcasts. Apple: https://lnkd.in/guesQvAV Spotify: https://lnkd.in/gKg2fmUj

“As anybody who's ever worked in a biopharma company knows, basically all the software that you're given is total crap.” A very frank answer from Jacob Oppenheim, Entrepreneur-in-Residence at Digitalis Ventures, to the question of what are the biggest challenges facing the biotech ecosystem. Do you agree? Listen to the Data in Biotech episode in full and share your thoughts below. Apple: https://lnkd.in/eUhQktfG Spotify: https://lnkd.in/egqs5fiH

“Organisations work best when everyone knows who their customer is.” Jacob Oppenheim, Entrepreneur-in-Residence at Digitalis Ventures, sat down with the Data in Biotech Podcast to give his take on the key ingredients biotech organisations need to scale up effectively. For more from Jacob, listen to the full episode here: Apple: https://lnkd.in/eUhQktfG Spotify: https://lnkd.in/egqs5fiH

We’re excited to share that Data in Biotech has officially hit 10,000 unique downloads! This podcast is dedicated to exploring how companies in life sciences leverage data to drive innovation - and for over 6 months, Ross Katz has sat down with experts from across the biotech world to dive into how they use data science to solve technical challenges, streamline operations, and push the boundaries of innovation. Now - 25+ episodes later and having cracked the Top 20 of Life Sciences Podcast in the US - we're excited to have reached this new milestone. A massive thank you to all our guests who’ve shared their expertise, and to you—our listeners—for your continued support. Here’s to the next 25 episodes! Pradeep Ravindra, Markus Gershater, Michelle Wiest, Miguel Cacho Soblechero, PhD, Ming "Tommy" Tang, Jesse Johnson, Harry Rickerby, Vera Mucaj, Cody Schiffer, Lana Denysyk, MPH, Annemie Ribbens, Wolfgang Halter, Joseph Pearson, Jacob Oppenheim, Pierre Salvy, Brendan McCorkle, Stewart Fossceco, Harshil Patel, Nathan Clark, Michael Nally, Guru Singh, Satya Singh, Amy Gamber, Jonathan Eads, Ryan Mork Listen to Data in Biotech wherever you get your podcasts. -- PS. We're going to be launching a new show soon that helps equip operational leaders with the real insights and tools they need to harness the potential of data. Drop a comment below and we'll send you the first episode when it launches.

We have a new episode of Data in Biotech to share! This week we're joined by Ryan Mork, Director of Data Science at Evozyne, to discuss how data science and machine learning are used in protein engineering and drug discovery. Ryan shared how Evozyne is utilizing LLMs and Gen AI to design new biomolecules, training the models with huge volumes of protein and biology data. He walked Ross Katz through the organization’s evolution-based design approach and how it leverages the evolutionary history of protein families, before digging into the different models being used by Evozyne, including latent variable models and embeddings. Finally, Ross asks Ryan to share his thoughts on the future of Gen AI and LLMs for biotechnology and how this area will develop over the next five years. Check it out wherever you get your podcasts. Apple: https://lnkd.in/eRYvmsUT Spotify: https://lnkd.in/e4BA_Zwb

“It's a combination of looking at what data is available and then going out and kind of sense checking it with what do you actually see on the floor.”   The detective work that is a key part of problem-solving issues in a manufacturing process was a big focus of our conversation with Amy Gamber, Vice President of Manufacturing at Atara Biotherapeutics. She explains how once you have the data, you then need to use your instinct to sanity check and identify the root cause of any problems.   For more on using data to better understand the manufacturing process, particularly in biotech, listen to the episode in full:  Apple: https://lnkd.in/eWNne_RR Spotify: https://lnkd.in/eBwbJxwa

When to intervene in a manufacturing process is a careful balancing act. Too early or unnecessarily, and you incur needless disruption. Too late or not at all, and you produce an unusable product.   When Amy Gamber joined us on Data in Biotech, she explained how she and her team use data to identify the critical and key parameters and the levers that can be pulled to influence them as part of Atara’s continuous monitoring program.   You can hear more about the processes Amy oversees as Vice President of Manufacturing at Atara Biotherapeutics in our latest episode:   You can also check out CorrDyn’s whitepaper on “Using Machine Learning to Implement Mid-Manufacture Quality Control in the Biotech Sector” for more on how we help businesses use data to improve manufacturing processes. Apple: https://lnkd.in/eWNne_RR Spotify: https://lnkd.in/eBwbJxwa